Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
109.80
+1.20 (+1.10%)
Streaming Delayed Price
Updated: 3:19 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
99
100
Next >
Merck Expands Tulisokibart Clinical Development Program With Initiation of Phase 2b Trials in Three Additional Immune-Mediated Inflammatory Diseases
October 06, 2025
From
Merck Sharp & Dohme
Via
Business Wire
1 Monster Stock in the Making to Buy and Hold
↗
October 05, 2025
This biotech company was relatively unknown a few years ago.
Via
The Motley Fool
Wall Street Hits Record Highs As Rate Cut Bets Offset Shutdown: This Week In Markets
↗
October 03, 2025
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via
Benzinga
Topics
Artificial Intelligence
Stocks
IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine
↗
September 29, 2025
Via
Stocktwits
Merck & Co's Options: A Look at What the Big Money is Thinking
↗
October 03, 2025
Via
Benzinga
U.S. Jobs Report Stalled Amidst Federal Shutdown: A Critical Information Vacuum for Markets and Policymakers
October 02, 2025
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been...
Via
MarketMinute
Topics
Bonds
Economy
These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap
↗
October 02, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via
Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
↗
October 02, 2025
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.
Via
The Motley Fool
Topics
Stocks
Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design
October 02, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...
Via
TokenRing AI
Topics
Artificial Intelligence
Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes
October 02, 2025
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a...
Via
MarketMinute
Wall Street Holds Firm Despite Shutdown and Weak Jobs Data
↗
October 02, 2025
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via
Chartmill
Topics
Economy
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
↗
October 01, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via
Benzinga
Topics
Government
Why Merck (MRK) Stock Is Up Today
October 01, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers.
Via
StockStory
Topics
Artificial Intelligence
Government
Wednesday's session: top gainers and losers in the S&P500 index
↗
October 01, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via
Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume.
↗
October 01, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Via
Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
↗
October 01, 2025
Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.
Via
Benzinga
Merck to Hold Third-Quarter 2025 Sales and Earnings Conference Call Oct. 30
October 01, 2025
From
Merck & Co., Inc.
Via
Business Wire
Global Markets Defy Headwinds: Resilient Sentiment Prevails Despite Shutdown Fears
September 30, 2025
As the third quarter of 2025 drew to a close on September 30, global financial markets demonstrated a remarkable display of resilience, largely shrugging off significant geopolitical uncertainties and...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape
September 30, 2025
September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge
September 30, 2025
Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...
Via
MarketMinute
Topics
Economy
Government
World Trade
What's going on in today's session: S&P500 movers
↗
September 30, 2025
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.
Via
Chartmill
Merck (MRK) Shares Skyrocket, What You Need To Know
September 30, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 5.7% in the afternoon session after the company announced positive results from its Phase 3 HYPERION trial for its drug, WINREVAIR™...
Via
StockStory
Topics
Artificial Intelligence
Tech Revolutionizes Cattle Feeding: A Sustainable Future for Livestock Markets
September 30, 2025
The global cattle feeding industry is at a critical juncture, facing mounting pressures from volatile feed costs, stringent environmental regulations, and a persistent labor crunch. In response, a wave...
Via
MarketMinute
Topics
Artificial Intelligence
Climate Change
Emissions
Discover which S&P500 stocks are making waves on Tuesday.
↗
September 30, 2025
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Via
Chartmill
Merck's Winrevair Cuts Clinical Worsening Risk By 76% Among Hypertension Patients
↗
September 30, 2025
Merck reported Phase 3 results showing Winrevair significantly reduced clinical worsening in pulmonary arterial hypertension patients.
Via
Benzinga
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
September 30, 2025
From
Merck Sharp & Dohme
Via
Business Wire
Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes
September 29, 2025
Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...
Via
MarketMinute
U.S. Government Teeters on Brink of Shutdown: Markets Brace for Uncertainty Amidst Data Blackout Fears
September 29, 2025
As the clock ticks towards the September 30, 2025, funding deadline, the United States federal government finds itself perilously close to another shutdown. Congressional leaders remain deadlocked on a...
Via
MarketMinute
Topics
Bonds
Economy
Government
Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program
↗
September 29, 2025
The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.
Via
Stocktwits
Topics
Government
Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers
September 27, 2025
In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and...
Via
MarketMinute
Topics
Economy
Intellectual Property
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.